Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma
Disease control
Recruiting now
This phase 1 trial tests whether giving the immunotherapy naxitamab more slowly, alongside standard chemotherapies irinotecan and temozolomide plus sargramostim, can reduce side effects in children with relapsed or refractory neuroblastoma. The study enrolls about 18 patients who…
Phase: PHASE1 • Sponsor: Steven DuBois, MD • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC